Acquired Company

Crescent Biopharma completed the merger with GlycoMimetics on June 16, 2025, and the combined company began trading on Nasdaq under the ticker CBIO.

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of new glucomimetic drugs to address unmet medical needs resulting from disease in the United States. The company is headquartered in Rockville, Maryland. Show more

P.O. BOX 65, MONROVIA, MD, UNITED STATES, 21770, Monrovia, MD, 21770, USA

https://www.glycomimetics.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

10.13M

52 Wk Range

$0.00 - $0.00

Previous Close

$0.16

Open

$15.70

Volume

N/A

Day Range

$0.16 - $15.70

Enterprise Value

4.579M

Cash

5.614B

Avg Qtr Burn

-5.106B

Insider Ownership

2.66%

Institutional Own.

47.77%

Qtr Updated

03/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Uproleselan (GMI-1271) Details Acute myeloid leukemia, Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Uproleselan (GMI-1271) +/- Daunorubicin and Cytarabine Details Acute myeloid leukemia	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Uproleselan (GMI-1271) +/- myeloablative, busulfan-based, pre-transplant conditioning Details Blood cancer, Acute myeloid leukemia	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Uproleselan (GMI-1271) +/-fludarabine & cytarabine Details Acute myeloid leukemia, Blood cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GMI-1687 Details Sickle cell disease	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rivipansel (GMI-1070) Details SCD (Sickle Cell Disease)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GMI-1359 Details Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.